Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...
The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...
GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...
"Developing new ways to treat these patients is of the utmost importance," Dr. Casey H. Halpern, a senior author of the study ...
Celebrity endorsements by Elon Musk and Serena Williams have pushed weight loss medication into the mainstream. Demand is so ...
Morning Overview on MSN
GLP-1 drugs deliver big weight loss but a catch is emerging
GLP-1 drugs like Ozempic have been hailed for their significant weight loss effects. However, recent research as of November ...
The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and ...
By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...
News-Medical.Net on MSN
Tirzepatide reveals a brain signal that predicts returning food preoccupation
Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in ...
At the 2025 Society for Neuroscience meeting, scientists discussed the adverse side effects of GLP-1 agonists and new ...
Two obesity medicine societies and an advocacy group have teamed up to produce US-specific evidence-based guidance on obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results